Company sells 6% secured notes to Amgen; inks collaboration agreement
By Devika Patel
Knoxville, Tenn., Feb. 22 – Unilife Corp. arranged a $55 million private placement of a 6% senior secured convertible note with Amgen Inc. on Feb. 22, according to an 8-K filed Monday with the Securities and Exchange Commission. Amgen also agreed to a collaboration under which the investor will use the company’s injectable drug delivery systems with Amgen’s product portfolio. The deal raised $30 million at pricing.
The note is convertible into common shares at a price equal to 90% of the volume weighted average price of the stock during the 20 trading days preceding the conversion, with a floor conversion price of $1.25. It matures on Feb. 22, 2023. The note may be put at 101.
The medical device manufacturer is based in York, Pa.
| Issuer: | Unilife Corp.
|
| Issue: | Senior secured convertible notes
|
| Amount: | $55 million
|
| Maturity: | Feb. 22, 2023
|
| Coupon: | 6%
|
| Conversion price: | 90% of the volume weighted average price of the stock during the 20 trading days preceding the conversion, floor of $1.25
|
| Put: | At 101
|
| Warrants: | No
|
| Investor: | Amgen Inc.
|
| Pricing date: | Feb. 22
|
| Settlement date: | Feb. 22 (for $30 million)
|
| Stock symbol: | Nasdaq: UNIS
|
| Stock price: | $0.98 at close Feb. 19
|
| Market capitalization: | $165.88 million
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
